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Abstract
Background: Xerostomia is one of the most prominent complications in
patients with Head and Neck cancers who receive radiation, as it usually
involves delivering a high dose to the salivary glands bilaterally.Xerostomia
significantly reduces quality of life (QoL) and only parotid gland sparing has
shown inconsistent results in improving xerostomia.
Materials and Methods: This was a prospective study in which locally
advanced (stage III/ IV) oropharynx, hypopharynx and supraglottic larynx cases
that were treated from January 2015 to April 2015were included. Out of the 37
patients, 17 were included in the study arm(contralateral SMG spared). Parotid
gland sparing was done in both the groups. The mean doses of the contralateral
parotid and submandibular glands were kept under 26Gy and 39Gy
respectively.
Xerostomia outcomes were assessed based on RTOG grading and patient rated
xerostomia specific QoLquestionnaire.
Results:The grading for xerostomia(of 2 or higher) at the end of treatment, at 3
and 6 months from commencement of treatment were 76%, 53% and 21%
respectively in the study group and 80%, 68% and 54% in the control group.
The difference at 6 months was statistically significant(p <0.009)
The xerostomia questionnaire scored by the patients at the end of 6 months
showed a mean score of 13 in the study arm against a score of 24 in the control
arm.
Conclusion:Sparing of the contralateral SMG in a selected group of patients of
locally advanced head and neck cancers using IMRT is feasible and results in
improvement of overall xerostomia outcomes which ultimately can lead to
better QoL.
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1. INTRODUCTION 
 
                   Head and neck cancers have been one of the most common 
malignancies for some time now and hence have garnered attention from 
various fields of oncology to improve the outcomes after treatment. As of 
now, the approach for locally advanced head and neck cancers is 
multimodality treatment. Radiation therapy has become an integral part in 
treatment of head and neck malignancies, and with improvement in 
techniques, it is now possible to reduce the acute and late complications 
related to radiation. 
  Dry mouth or xerostomia is one of the most common 
complications seen in patients treated for head and neck cancer that 
occurs during and after completion radiotherapy. This is attributed to the 
damage caused to the salivary glands that get included in the radiation 
fields, which is irreparable. Other than significantly impairing the quality 
of life (QoL) of patients who are potentially cured of their cancers, it may 
also leave behind severe long term disorders [1].  
The major salivary glands involved in salivation are parotid and the 
submandibular glands. Since the salivary glands are considered to 
function as parallel organs with respect to late radiation induced effects 
[2], preservation of the salivary function can be expected if irradiation of 
large volumes of the major salivary glands can be avoided. 
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Although parotid sparing IMRT is now being practised at many centres 
and has become standard of care [3], sparing of only the parotid glands 
has inconsistently resulted in improvement of xerostomia [4, 5].  This 
seems to be attributable to the fact that mucin, an important component of 
saliva that helps in maintaining a subjective sense of hydration is lacking 
in the saliva secreted by the parotids.  
The sub mandibular glands secrete saliva rich in mucin which influences 
the subjective feeling of mouth dryness. 
 
Hence, to understand the significance of sparing submandibular glands, it 
is essential to know the anatomy and physiology of sub mandibular 
glands, and the effect of radiation on them. 
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Anatomy: 
The human salivary gland system is exocrine type and can be broadly 
divided into two groups.  
i) Major salivary glands - Parotid 
                 - Submandibular      
 
                                        - Sublingual 
 
ii) Minor salivary glands – mucosa of tongue, gingiva and oropharynx 
 
The sub mandibular is located in a space called as sub mandibular 
triangle. 
Boundaries: Superior- Inferior edge of mandible 
          Inferior- anterior and posterior bellies of diagstric muscle 
 
The submandibular gland triangle consists of the following structures 
within it – submandibular lymph nodes, facial artery and vein, mylohyoid 
muscle, and three nerves, namely- lingual, hypoglossal, and mylohyoid. 
Major portion of the submandibular gland lies posterolateral to the 
mylohyoid muscle.  
 
Excretory duct: 
Wharton’s duct is the main excretory duct that drains the submandibular 
glandt. It runs above the hypoglossal nerve and inferior to the lingual 
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nerve. The duct opens in the floor of mouth lateral to the lingual frenulum 
at the level of lower incisors.  
 
Nerve supply:  
Parasympathetic- i) Secremotor fibres- facial nerve(CN VII) 
         ii) Lingual nerve (branch of mandi. division of CN V)  
Sympathetic- superior cervical ganglion 
 
Arterial supply- Submental and sublingual arteries (branches of facial and 
                           lingual arteries) 
 
Venous drainage- Anterior facial vein  Common facial vein  IJV 
 
Lymphatic drainage-  Prevascular and postvascular lymph nodes 
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Diagrammatic representation of the major salivary glands 
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Physiology: 
The salivary glands are broadly classified into two types based on the 
type of cells they are comprised of, that is, serous or mucinous or both. 
Parotid gland mainly comprises of serous cells. On the other hand, 
submandibular gland contains cells of both serous and mucinous types 
[6]. 
 
Furthermore, salivary secretion is divided into two types- stimulated and 
unstimulated salivary flow. Most of the stimulated saliva is produced by 
the parotid glands and while eating, the secretion becomes maximum. 
Submandibular glands produce almost 90% of the unstimulated salivary 
output. Unstimulated salivary flow is mainly contributed by the sub-
mandibular glands and is at 0.3ml/min [7], which decreases to about half 
during sleep [8]. 
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There are various factors affecting the salivary flow, and they are 
different for stimulated and unstimulated flow [10].   
FACTORS AFFECTING STIMULATED SALIVARY FLOW: 
 Mastication 
 Taste 
 Olfaction 
 Vomiting 
 Aging- not clear[9]  
The above mentioned factors cause stimulation of salivary flow. Chewing 
alone can cause increase in salivary flow.  But, the stimulation is greater 
when a person activates both chewing and taste senation.  
Of the four basic taste sensations – salt, acid, bitter and sweet; acid is the 
strongest stimulant of salivary flow [7]. In fact, for measurement of 
salivary flow during various tests, citric acid is the most commonly used 
substance to induce flow [11]. 
 
FACTORS AFFECTING UNSTIMULATED SALIVARY FLOW: 
 Dehydration- decreases 
 Smoking- varied  
 Posture(sitting/ standing)- increases in standing position 
 Drugs 
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To explain the effect dehydration has on unstimulated salivary flow- just 
2% decrease in body weight because of dehydration can decrease salivary 
flow by 60% [12]. But if there is only a loss 8% of total body water, it 
can result in stoppage of complete salivary flow [7].  
 
Although, dehydration shows strong correlation with decreased salivary 
flow rates, serum creatinine and urine osmolality, considered as the 
standard metabolic markers for dehydration, do not correlate well with 
flow rates of saliva [13].  
 Salivary flow rates are the lowest at night, but during daytime they can 
vary. There is also a seasonal variation seen with flow rates, and they 
reach their highest during winter.  [7, 14, 15]. 
Smoking has found to show varied effect (increases/ decreases/ no 
change) on salivation according to different studies [16, 17]. 
 
To know the importance of sparing the salivary glands from receiving 
high dose, it is essential to know the functions of saliva. 
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FUNCTIONS OF SALIVA [18] 
 Lubrication 
 Digestion 
 Solvent action 
 Buffering action 
 Remineralization 
 Temperature regulation 
 Antibacterial/ antifungal action 
 Production of regulatory peptides and growth factors 
 
The effect of saliva on swallowing is not as straight forward as the above 
mentioned functions. Saliva helps in the formation of food bolus by 
softening the food mechanically and also due to its enzymatic action. It 
then helps in initiation of swallowing and also aids in lubrication of the 
bolus to provide a smooth passage. 
Although, the patients post radiation therapy complain of difficulty in 
swallowing, the measurement of bolus transit time and swallowing 
function did not correlate well [19, 20].   
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Xerostomia: 
           Xerostomia has two components - decrease in salivary output along with 
change in its composition which is objective, and subjective feeling of 
dryness as reported by the patient. Decreased salivary outflow leads to 
number of secondary effects that is sometimes called as xerostomia 
syndrome. 
Xerostomia can be divided into two types based on when it is seen from 
the initiation of treatment.  
  - Acute/ early (<90days from the initiation of treatment) 
  - Chronic/ late (>90 days from initiation of treatment)   
 
Permanent or chronic xerostomia is the most common late side effect of 
radiation therapy for head and neck cancers and is considered by patients 
as a major cause of decreased quality of life (QoL) [21, 22]. 
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EFFECTS OF XEROSTOMIA: 
 Decreased salivary output can affect the taste resulting in reduced 
taste sensation after completion of radiation therapy and cause a 
delay in its recovery. 
  It is also supposed to contribute to nutritional deficiencies due to 
difficulty in mastication and deglutition. 
 Mucosal fissures and ulceration  
  Dental caries and also some infections can be seen as a result of 
change in the composition of flora in the oral cavity. The risk of 
osteonecrosis of mandible can increase when there is reduction in 
the salivary flow [22].  
It may also lead to decreased acid clearance by salivary 
bicarbonate which can result in oesophageal injury [23].  
 
Xerostomia and mucositis: 
Xerostomia and mucositis are common side effects associated with 
patients undergoing radiation therapy for head and neck cancers.  
It has been suggested that xerostomia can predispose the development of 
mucositis or increase its grade of severity. 
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This hypothesis is based on 
- antimicrobial activity of the saliva 
-  protective effect of salivary mucins on the mucosa 
- secretion of growth factors such as epidermal and fibroblast growth   
  factor in saliva[24].  
 
Few studies where it was found that xerostomia increases risk for 
mucositis in patients who receive chemotherapy and the decrease in 
incidence of chemo induced-mucositis when pilocarpine is used[25] 
support the above mentioned hypothesis. 
 
 On the other hand, there are some experiments and clinical obsevations 
which suggest that the relationship between mucositis and acute 
xerostomia is more likely to be coincidental rather than causative.  
It is more likely that during their initial stages, they occur as independent 
events. But, during the treatment, reduction in salivary output (protective 
salivary proteins) may make the mucosa more susceptible to radiation 
exposure which results in bacterial colonization of the epithelium causing 
increased and extended mucosal injury. 
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Pathophysiology of radiation induced xerostomia  
Radiation-induced xerostomia begins during the early part of treatment. 
Salivary flow may decrease by 50 to 60% in the first week.. After 6 to 7 
weeks of radiation therapy, flow decreases to approximately 20% [26].  
 
Studies have shown that patients receiving RT; during the first two weeks 
of treatment, a rapid fall in salivary flow is seen [27].  
After completion of 2 weeks of RT, at about 20Gy, only 20% of the 
original flow of saliva is retained by the major salivary glands. Even after 
6 weeks of radiation, recovery did not seem to occur. Compared to the 
other salivary glands, the parotids lost more of its function- losing its 
flow to almost 0% whereas the other salivary glands retained up to 20% 
of their salivary flow [28, 29, 30]. 
However, it was noted that the difference in radiosensitivity of parotid 
and submandibular glands was clinically insignificant [31].  
 
In the early part of 20th century, an eminent radiobiologist, Bergonie had 
described the radiosensitivity of salivary glands difficult to understand 
[32]. This was because the acinar cells/ excretory or functional cells of 
the salivary glands were highly well differentiated and had a slow 
turnover but responded like acute responding tissues to radiation. Tissues 
with slow mitotic rate have less radiosensitivity. 
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HYPOTHESES FOR RADIOBIOLOGY OF SALIVARY GLANDS 
 The first concept that was suggested was the granulation 
hypothesis which stated that the membranes of secreting granules 
in acinar cells are damaged by lipid peroxidation which is induced 
by radiation. This results in leak of proteolytic enzymes from 
granules which caused immediate lysis of cells [33]. 
However, a study was done early after radiation in which salivary 
gland scintigraphy (SGS) was performed and it showed that there 
was no effect on trapping of technetium-pertechnetate, although 
there was severe reduction in saliva excretion [34]. 
This finding seemed to indicate that though the excretory function 
was impaired, the gland volume was not affected. So, cells of the 
salivary gland producing saliva did not disappear but lost their 
function during the first few days of radiation.  
 
 Two separate mechanisms were proposed by Konings et al to 
explain radiation induced salivary gland dysfunction. 
- First, because of selective membrane damage, there is a defect in 
cellular functioning which impairs the receptor mediated signalling 
pathways of water excretion. No immediate cell death or lysis 
takes place. 
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- Late damage is explained by classical cell killing of progenitor 
cells and stem cells, thus inhibiting proper cell renewal, and by 
damage to the cellular environment, causing a shortage of properly 
functioning secretory cells [35]. 
The decline in salivary function continues up to several months after 
radiation therapy [36]. Till 12 to 18 months after radiation, some recovery 
is possible which depends on the radiation dosage of the salivary glands 
and the volume that was included in the treatment fields. However, in 
many cases, xerostomia becomes an irreversible, problem which last for 
life [37, 38].   
Braam et al reported that even many years after radiation, there still 
could be recovery salivary output, with an increase of about 32% in the 
flow from 1 to 5 years after completion of treatment [39]. 
This is not generally accepted, and most studies have shown that over a 
period of time, there was little recovery in the patients who did not 
receive some sort of radiation technique where salivary gland was spared 
[40].  After treatment of head and neck cancers, the prevalence of 
xerostomia relates to the high radiosensitivity of the salivary glands. 
During the first week of radiation, after about 5 to 10Gy, saliva 
production decreases by 60 to 90% with recovery seen later if the 
radiation dose is moderate [41, 42, 43]. 
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EFFECT OF RADIATION ON SEROUS AND MUCINOUS GLANDS 
The mechanism by which damage occurs to acute salivary function is not 
clearly understood. 
The cells of parenchyma of salivary glands have low mitotic activity. It is 
unlikely that DNA damage which results in reproductive death is soccurs 
during and just after completion of radiation.   
Acute inflammatory infiltrates are seen along with degenerative changes 
in parenchymal cells as early as 24 hours after the first radiation dose. 
This is more pronounced in serous compared to mucinous cells [44]. 
As the radiation dose increases over a period of time and the dose 
accumulates, the degenerative changes increase over a period of time, and 
the glands become atrophic and fibrotic. It was observed by Stephens et 
al in primates’ glands that degenerative changes increase in intensity with 
dose and time, mainly in the serous acinar cells [45]. Two types of 
damage were described: apoptosis at low doses and at high doses, 
necrosis [46]. 
The reduction in watery content of saliva seen initially is attributed to the 
serous acinar cells because of their high sensitivity to radiation. 
Relatively, its mucin content, other proteins and minerals remain stable. 
So initially, there is an increase in concentration of these contents. 
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Soon after the radiation starts, the salivary secretion is sticky due to initial 
reduction in its watery content. Mucinous contents of the saliva also 
diminish over time, and resulting in disappearance of the sticky saliva. 
Image showing the different type of cells in the submandibular gland 
 
 The serous cells are more sensitive to radiation effects resulting in 
decerease in the watery content of the saliva initially 
 Mucous cells eventually also are affected causing decrease in the 
mucinous salivary content. 
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Measuring Xerostomia 
To properly assess the severity of xerostomia, measurements that can be 
done with accuracy and reliability are required as it also helps in knowing 
about its time course and dose response relationships. This will also help 
in assessing the efficacy of measures to be taken to protect the glands or 
stimulate salivary production after irradiation. 
 
Currently available measurements of xerostomia include  
(1) measuring gland activity using functional imaging 
(2) measuring salivary output 
(3) observer- rated grading of toxicity 
(4) instruments that assess patient- reported xerostomia- related    
      symptoms.  
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Salivary Gland Imaging 
Scintigraphy with 99M Tc pertechnetate can be used to image the 
functional activity of the salivary glands. 
It gives information related to the uptake, concentration and the excretory 
phase of salivation. Here, uptake means the movement of fluid from 
serum to the glands. The movement of saliva and its modification when it 
passes from the duct system to the mouth defines excretory phase.  
Using scintigraphy, the affect radiation has on various phases of gland 
activity can be deciphered. 
It has also been shown that the results obtained through scintigraphy and 
measurements of salivary output have reasonable correlation [47].  
When combined with SPECT (short for single photon emission 
tomography), it can not only provide spatial information about the 
anatomical volumes of glands but also give information about response of 
the salivary glands to different radiation doses, something that cannot be 
done using other methods [48]. 
The downside for this method is the technical complexity of the 
procedure and need for a separate department of nuclear medicine. 
Hence, for routine clinical assessment of xerostomia, use of scintigraphy 
is not in practice. 
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Image showing uptake in the salivary glands after Salivary 
gland scintigraphy(SGS) 
1, 2- parotid glands                 4, 5- submandibular glands 
7- oral cavity 
3- background for parotid glands 
6- background for submandibular glands and oral cavity 
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Salivary Output Measurements 
The most commonly used measures to grade xerostomia objectively are 
measurements of salivary output. 
These include -   collections of unstimulated saliva 
     -   collections of stimulated saliva which represent salivary  
          output during eating 
- whole mouth saliva 
- or selective output from each gland 
 
 
SALIVARY COLLECTION: 
Saliva is usually collected over a period of 5 minutes.  
a) Collection of whole saliva- This is done by spitting into a container, 
drainage of the saliva or by measuring the weight of cotton rolls that are 
inserted in the mouth. 
To stimulate, the commonly used method is application of citric acid 
(2%) which is a strong stimulant, to the dorsum of the tongue or, by 
chewing which causes mechanical stimulation.  The weighing of the 
collected saliva is done and then the volume is determined with an 
assumption that the specific gravity is 1, and finally the rate of saliva 
flow is calculated in mL per min. 
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b) Selective collection of parotid gland saliva- This is either done by 
placing a catheter in the parotid duct or, using a suction cup. 
The suction cup has a central chamber into which the saliva flows and its 
outer chamber is used to apply suction so that the cup adheres to the 
buccal mucosa. 
 
c) Collection of submandibular/ sublingual gland saliva- This can be done 
by similar methods used to collect parotid gland saliva but the suction is 
performed on the gland orifices over the floor of the mouth.   
 
There is no method that has proven to be satisfactory for selectively 
measuring the function of minor salivary glands after RT. For patient’s 
suffering from Sjogren’s syndrome, there are reports which have shown 
methods for measurements of minor salivary gland output from the lip 
mucosa.  
However, in irradiated mucosal surfaces, the flow from minor glands 
residing over these surfaces have high likelihood of being affected by the 
parotid and submandibular secretions. 
 
Drawbacks: The results of salivary output measurements obtained by 
different methods may not be comparable in different studies. This is 
because of the differences in the collection methods and their duration, 
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the type of stimulants used and period of time for which they were 
applied [46]. 
There are other factors which may affect output of saliva that might be 
neglected and are supposed to be standardized, like, the variation in 
salivary output during daytime, effects of posture and effects of 
hydration.  
 
CHOICE OF SALIVARY COLLECTION METHOD 
Based on the investigation or the test that is being performed, the method 
of saliva collection varies. 
Whole saliva may not be only the sum secretions of individual major 
gland. This is as it is admixed with secretions of minor salivary glands 
and many non salivary components. Bacterial products, food particles 
that have been left behind, desquamated cells and debris form the non 
salivary components. Some of the saliva may be bound to surface of the 
mucosa [50]. 
Hence, studies of dose/ response relationships of the salivary glands are 
considered most reliable when selective salivary gland measurements are 
performed or when SGS is used. 
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 On the other hand, when general xerostomia or the relationship between 
the salivary output and symptoms produced are being studied, measuring 
whole saliva is usually considered as satisfactory. 
 
Unstimulated saliva measurements are the eaiest to perform. 
However, they are very sensitive to the hydration status of patients, which 
may be vary drastically in certain conditions like the weight loss seen in 
patients during and shortly after radiation, and use of medication that 
induce xerostomia [51, 52].  
Stimulated whole-mouth saliva depends on the type of stimulus used and 
duration for which it was applied. For comparisons, both interpatient and 
interstudy, a standard method of collecting saliva is essential. 
Navazesh et al has given detailed guidelines for collection of saliva [53]. 
 
METHODS/ PRACTICES TO BE FOLLOWED FOR SALIVA 
COLLECTION 
 
 Ideally, the patient should not eat or drink, or even gargle/ brush 
for a minimum of 2 hours before collection.  
 Collection in the morning is preferable, as the saliva production 
varies during the daytime physiologically.  
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 To make sure that the saliva moves to the anterior part of the 
mouth, the person is made to sit with a slight forward tilt of the 
head.  
 After swallowing the initial saliva, it is allowed to be drained along 
the lower lip into a funnel, which is placed in a container. 
At the end of the collection period (5 minutes), the subject 
expectorates residual saliva from the mouth. 
 
The drugs taken by the patient should be noted, and those which may 
affect the salivary output should be taken into account. This is helpful in 
studies that use output of saliva as an endpoint or a variable.  
 
There have been several studies that have included measurements of 
salivary contents like mucins, pH, proteins and inorganic solutes after 
radiation therapy. 
However, there were large inter-individual variations and due to lack of 
correlation with other aspects of xerostomia these factors are not 
routinely used for saliva assessment in studies [54].  
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Observer assessed toxicity rating 
The most commonly followed xerostomia rating that is observer based in 
that proposed by the RTOG. 
 
RTOG Grading System for Xerostomia 
A. Acute (within 90 days from the commencement of RT) 
Grade 1: Slightly thickened saliva, additional fluids may be required 
Grade 2: Thick, sticky saliva. Alteration in diet is required 
Grade 3: Inadequate oral nutrition related to salivary gland changes 
Grade 4: Acute salivary gland necrosis 
 
B. Chronic (Beyond 90 days from the commencement of RT) 
Grade 1: Slight dryness of the mouth; good response to stimulation 
Grade 2: Moderate dryness of the mouth, poor response to stimulation 
Grade 3: Complete dryness of the mouth; no response to stimulation 
Grade 4: Fibrosis 
 
 
 
 
 
 
 27 
The RTOG scoring criteria of xerostomia has been divided into acute and 
chronic. 
Acute xerostomia (occurring within 3 months of commencement of 
therapy) is graded primarily based on symptoms 
- degree of dry mouth 
- thick saliva 
- altered taste 
Chronic xerostomia (occurring 90 days after initiation of RT) scale is 
graded based on  
-  degree of mouth dryness 
-   response to stimulus. 
 
It is not stated whether these are observer rated or patient reported. Also, 
the response to stimulus is not defined. 
Grade IV which is acute salivary gland necrosis or late salivary gland 
fibrosis is observer rated.  
Hence, this grading system has disparities that need to be sorted out and 
proper validation of this grading system has not been done. 
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LENT-SOMA scoring system of xerostomia [55] 
This is a more extensive scoring system which includes several 
paramateres. 
 Subjective grading consisting of an evaluation of dryness and 
whether it is debilitating or not; 
 Objective findings of mucosal moisture  
 Management issues like the frequency of saliva substitutes, which 
are highly dependent on patients’ threshold to symptom 
 Salivary flow relative to the pretreatment flow.  Arbitrary cut off 
values of salivary flow rates relative to the pre-RT flow rates were 
assigned to the various grades. 
 
The main drawbacks/ deficiencies of these scoring systems include 
- information regarding who does the grading is vague 
- lack of clear boundaries between the grades (eg, whether dryness is mild 
or moderate or whether it is moderate or complete), 
- salivary flow reduction to different grades has been arbitrarily assigned 
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Xerostomia Symptoms and Related QOL Assessments 
Xerostomia/ dry mouth is a symptom and so, the patient’s reporting of the 
extent of severity is the most vital factor that needs to be assessed and 
scored. To properly grade/ rank the severity of xerostomia, it is 
mandatory to develop an instrument that allows its scoring with reliability 
and which is also sensitive. 
 
 A simple question regarding mouth dryness will not cover the various 
aspects of xerostomia. Therefore, development of many instruments with 
several questions has been done.  
Typically, the xerostomia questionnaires include questions pertaining to  
the difficulties related to xerostomia that the patients have to rate which 
are related to chewing, swallowing, talking, and sleep and their need to 
sip water while eating food or at rest. Various methods are applied for 
scoring each item and then a summary of all the items is made to get a 
cumulative score.  
Some xerostomia-specific questionnaires have been tested to know if they 
are valid and reliable, as well as consistent and sensitive [56-58]. 
 A few questions related to xerostomia have been incorporated in several 
comprehensive head and neck cancer-related QOL instruments [59-64].  
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Tests for these instruments as a whole for validity and reliability have 
been done, but, separate testing of the questions that are related to 
xerostomia has not. 
In the clinical practice of head and neck cancer treatment, observer-
defined toxicity grading is prevalent.  
 
Eisbruch et al - Proposed New Grading of Symptoms and 
Toxicity 
Eisbruch et al proposed a new grading system in an effort to achieve a 
clinically meaningful separation between the various xerostomia grades.  
The grades were defined according to the functional difficulties that 
xerostomia caused. 
Grade 1 xerostomia – causes no disability, grade 2 was defined as dryness 
which would require additional fluids for swallowing and grade 3 was 
dryness which caused patients to alter their diet, and interference with 
sleep, speaking or other daily activities.  
 
Using this proposal of new system to grade xerostomia, it would be easier 
to set an endpoint that was clear while conducting trials of post-radiation 
therapy improvement seen in xerostomia. 
This could include the reduction in the rate of grade III hyposalivation, 
which is associated with functional difficulties that are clinically relevant. 
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IMPROVEMENT OF XEROSTOMIA OVER TIME POST RT 
It was found that xerostomia symptoms improve over time, especially if 
sparing of part of the major salivary glands has been done.  
In the study done at University of Michigan, it was found that the 
xerostomia scores that were reported by patients (who had bilateral neck 
irradiation) showed gradual improvement when sparing of partial parotid 
gland was done. This was more pronounced during the second year after 
completion of radiation therapy. After 24 months, it was found that their 
xerostomia scores were almost comparable with the patients who had 
only one side of the neck irradiated [65]. 
Similarly, another study of intensity-modulated RT for nasopharyngeal 
cancer showed that patients who had grade II xerostomia during the first 
year post radiation, improved to grade I or no xerostomia 2 years after 
radiation therapy [66]. 
 
The reasons for the improvement in symptoms may be attributed to the 
salivary glands that were spared partially being able to increase the saliva 
production or the patients themselves who were able to adjust over a 
period of time. This improvement seemed to be continuous.  
Therefore, separation of xerostomia into acute and late may not be 
entirely necessary; however, it is important that during the assessment of 
symptoms, the point of time at which it is being done is defined.  
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Proposed New Grading System for Xerostomia 
 
A. Subjective 
Grade 1: No disability 
Grade 2: Dryness requiring additional fluids for swallowing 
Grade 3: Dryness causing dietary alterations, interference with sleep, 
speaking or other activities 
 
B. Objective* 
Grade 1: Flow >0.2 mL/min 
Grade 2: Flow 0.1–0.2 mL/min 
Grade 3: Flow <0.1 mL/min 
*Whole-mouth, unstimulated flow rates. 
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IMPACT OF XEROSTOMIA ON QUALITY OF LIFE (QoL) 
The patients treated for Head and Neck cancers with radiation have their 
QoL post treatment influenced strongly by xerostomia and the other 
effects it causes. 
 
A survey conducted by Epstein et al in which, 65 patients who had 
survived for more than 6 months post RT were included.  
It showed that   92% of the patients had dry mouth 
        43% had difficulty in chewing 
        63% had dysphagia 
        76% had loss of taste sensation 
        51% had altered speech 
                           48.5% had difficulty with dentures 
                38.5% had increased tooth decay  
 
Pain was commonly seen in these patients and interfered with daily 
activities in 31% of the patients. More than 50% of the patients had mood 
complaints. 
60% of the patients had interference in their social activities because of 
their physical condition [67]. 
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Mastication/ manipulation: Most patients who develop xerostomia have 
to adjust their diet due to the difficulty that they experience while eating 
food, although it is sometimes done unconsciously [68]. 
It becomes uncomfortable and sometimes painful to masticate and 
manipulate food in the oral cavity and so most patients need to sip water 
frequently while they are eating and there is still a chance of food getting 
stuck in their mouth or throat [69]. 
Swallowing: Along with chewing, swallowing difficulty is also a problem 
that these patients have to face. After radiation to the neck, the 
pharyngeal structures have their mobility decreased in general, which 
leads to increase in transit time in the pharynx and a delay in closure of 
larynx [70, 71]. 
A study was done where swallowing function of patients (a year after 
completion of radiation) and healthy volunteers was compared.  
Patients showed abnormal bolus transport which was found to be 
significant. It was found that beginning of elevation of hyoid bone 
happened a little later, compared to the healthy volunteers and that 
position of hyoid bone was held for a longer time.  Consequently, it was 
also noted that the upper esophageal sphincter opened too early with 
respect to the when the food bolus arrived [72]. 
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Other changes included   
- Reduction in contact of base of the tongue to the 
pharyngeal wall 
- Restriction in motion of larynx 
-  Impairment in closure of the vestibule of larynx, true 
vocal folds, which resulted in aspiration [73, 74] 
Taste perception: When the mucosa of oral cavity and pharynx is 
irradiated, damage of taste receptors occurs, which leads to increasing 
compromise in taste discrimination [75]. 
Taste may be affected by decrease in salivary output, which often 
contributes to the slow return of taste perception after radiation therapy. 
This is mainly observed after 2 months, when sensation of bitter and salt 
are generally impaired the most. 
Although, during the first year, taste sensation recovers gradually, it is 
observed that even 1 to 2 years after completion of therapy, partial loss is 
still present [76]. 
Speech: Difficulty in speech is another complaint commonly present in 
patients who have developed xerostomia due to radiation exposure [77, 
78]. 
 Even after 5 years, patients still perceive that they have problems of 
speech, find it difficult to be understood, and also diminished 
intelligibility [79]. 
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Dental caries: There are a number of factors that secondarily increase the 
risk of dental caries  
- The normal flora of the mouth becomes more 
cariogenic (eg, increased colonization with 
Streptococcus mutans and Lactobacillus), 
- decrease in the pH of saliva 
-  alteration of  immunoglobulis, and 
-  loss of mineralizing components [80–82]. 
 
Osteoradionecrosis: Risk of osteoradionecrosis of mandible may increase 
due to decreased salivary flow [83]. 
 
Oesophageal injury: Xerostomia leads to decreased salivary bicarbonate 
which can lead to inadequate clearance of acid causing esophageal injury 
[84]. Ulcers and fissures of mucosa are more commonly seen if the oral 
mucosa is dry [85]. 
 
Xerostomia syndrome: The aforementioned secondary effects caused by 
xerostomia contribute to the syndrome referred to as xerostomia 
syndrome. 
In the end, these factors can result in decreased nutrition and loss of 
weight, which can lead to  major health issues [86, 87] 
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Prevention of Xerostomia 
Cytoprotectants 
For protection of normal tissues from the ill effects of radiation and 
chemo drugs, many agents have been developed. 
Amifostine (WR-2721, Ethyol1), which is a byproduct of the nuclear 
warfare program, has been recognized as a radioprotector with potential 
for a long time. 
 
Mechanism of action: 
                     Amifostine enters the bloodstream 
                                            Hydrolysed by alkaline phosphatases  
                           Active form WR-1065  
            Enters nuclei of cells 
                        Scavenges free radicals  
 
          Prevents damage caused by radiation to DNA  
It has been suggested that normal tissues are protected selectively as the 
tumour endothelium lacks alkaline phosphatases and the acidic conditions 
in the microenvironment prevent the activation of amifostine within the 
tumour [88]. 
However, from the data gathered from preclinical studies, the results are 
not clear, and the issue is still contested [89-91]. 
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Brizel et al., a Phase III trial. 
This was a randomized study where 303 patients who were treated with 
conventional radiation therapy for Head and Neck cancer (both 
postoperatively and as primary modality) were given amifostine every 
day before radiation (200 mg/m2 intravenously).  
Results- The incidence of acute xerostomia grade 2 or higher had 
significant reduction (78% to 51%) with the use of Amifostine and there 
was reduction in grade 2 or higher chronic xerostomia from 57% to 34%. 
The disease control or overall survival was not altered [92]. 
  
As the consequence of this study, use of amifostine received approval 
from the U.S. Food and Drug Administration (FDA). Recently, a follow-
up study was published, and it suggested there was reduction in 
xerostomia even up to 2 years after completion of treatment with the use 
of amifostine. No difference was seen in local control or overall survival 
even after 2 years [93]. 
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A recent meta-analysis tried to overcome the problem of detection small 
differences in survival. It was found that, amifostine caused reduction in 
the risk of acute grade 2 or higher xerostomia by 76% and the risk was 
reduced by 67% for late xerostomia in patients who were treated with 
radiation therapy [94]. 
It was also found that effectiveness of treatment was not weakened by 
addition of amifostine. 
 
During Concomitant chemoradiation:  
In concurrent chemoradiation, usage of amifostine has been a controversy 
[95]. 
There has been no RCT that has shown that there may be an indication 
for the using amifostine, so it probably should not be done outside a 
clinical study [96]. 
  
Toxicity: Nausea and emesis are common side effects, but usually mild 
and are effectively controlled with the use antiemetic drugs.  
When given intravenously, amifostine increases the risk of transient 
hypotension but it is not seen with subcutaneous usage [97]. 
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Submandibular gland transfer 
Although it is a less wide-spread approach, salivary gland transfer is an 
option that has been used in patients for prevention of xerostomia. 
 
Jha et al. and Seikaly et al. were the first to propose transfer of one 
submandibular gland surgically to the submental space, outside the field 
of radiation [98, 99]. Altough practically, this can be done only for the 
patients who have been planned for post-op radiation therapy. This is 
because the transfer is done as part of the surgical procedure. 
It is not always easy to predict which patients would require post-op 
radiation, and few patients may not be willing for further treatment. In 
few patients, the shielding of the submental space may not be possible 
due to its proximity to the high risk region.  
 
In the largest study so far, 28% of the total patients (n= 60) who 
underwent transfer of salivary gland, either did not receive post op 
radiation or if they did, it was without the relocated gland being spared 
from radiation [100]. However, after the transfer, all of the relocated 
survived and were functioning well. There were no complications during 
the surgery with an average of 45 minutes operative being added. 
The results showed that 81% of the patients had no xerostomia/ grade I 
xerostomia and only 19% had grade II or higher.  
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A recently updated long term follow up study showed that the salivary 
flow was normal in 83% of patients even after 2 years of radiation 
therapy [101]. Other studies have also shown results that were similar; 
however, transfer of salivary gland should not be done as a procedure in 
standard practise [102, 103]. 
 
Institutional experience with this technique is essential, and the procedure 
requires careful patient selection with proper assessment of the benefit 
that the procedure may give. 
Without proper experience, it is highly probable that many of the patients 
undergoing the procedure will do so without gaining the actual benefit. 
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Salivary gland sparing RT- parotid 
The damage caused by radiation depends on the volume of tissue that 
receives radiation and the dose that it receives. Therefore, the right way 
of preventing radiation-induced xerostomia would be to see to it that the 
radiation is focussed on the target volume and avoid irradiation to the 
salivary glands when deemed unnecessary. 
Using 3D Conformal radiation therapy and Intensity modulated 
radiation therapy, it is possible to spare a part of the parotid in clinical 
practice [104]. A small portion of the parotid that is located close to the 
tumour receives high dose of radiation, whereas a low dose is 
administered to rest of the gland. Parotid sparing has been used in many 
centres for prevention of permanent xerostomia [105-108]. 
  
At the Leuven University Hospital, a relatively simple 3D-Confromal 
technique (without the use of intensity modulation) has been in clinical 
practice since 1999 for sparing the contralateral parotid gland [104]. 
  
Although it has been tried and implemented to spare the contralateral 
parotid using this technique, it is not always possible. Patients who have 
tumours that are placed in the midline or those that cross the midline have 
to be excluded. Presence of contralateral lymph node metastasis is also a 
criterion for exclusion. 
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If these limitations are respected, then the use of 3D- Conformal radiation 
therapy or intensity modulation does not cause increase in risk of tumour 
recurrence in the region that was spared. 
 
There also is evidence that suggests that there is improvement in 
quality of life with reduction of xerostomia. Lin and colleagues reported 
that there was significant improvement in both xerostomia and quality of 
life scores over time during the first year after using intensity modulated 
radiation therapy [109]. 
Jabbari et al also conducted a matched case–control study, in which it wa 
observe that after IMRT, there was improvement in both xerostomia and 
quality of life with time, but this was not observed after conventional 
radiation therapy.  
The potential benefits gained from IMRT were best observed a little late 
after completion of radiation (>6 months) [110]. 
 
Dose for parotid sparing 
The doses and the volumes that can be irradiated to permit preservation 
of salivary flow after RT have studied and the data is emerging. 
 Usually, the dose distributions in parotid glands are compared 
with residual saliva production. This correlation helps in making 
dose/volume-response relations for function of parotid gland 
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It has become clear that the relationship between reduction in 
saliva flow and mean parotid dose for each gland is exponential. This 
suggests that there is a threshold mean dose for parotid gland that should 
not be exceeded if adequate gland function has to be retained [111]. 
 
Literature support: Eisbruch et al proposed a mean parotid dose of <26 
Gy as a dose constraint that had to be met if adequate function was to be 
retained [112].  
A study done in Washington University also reported similar 
results. It was shown in their results that, if the mean parotid dose 
exceeded 25.8 Gy, it would likely decrease the flow of saliva to 25% of 
its flow before commencement of treatment. 
The reduction in the incidence of xerostomia was significant when the 
mean parotid dose of at least one gland was kept below 25.8 Gy [113]. 
 
There have been studies where SGS (Salivary gland scintigraphy) was 
used to assess parotid function after radiation and similar results were 
reported: a mean parotid dose which did not exceed 26 to 30Gy allowed 
retention of salivary gland function [114].                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
Hence, it was concluded that if a mean parotid dose of <26 to 30Gy was 
used as a planning objective, significant reduction in xerostomia could be 
achieved [115]. 
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2. LITERATURE REVIEW 
1. Saarilahti et al [107] 
This was the first study that checked for the feasibility of submandibular 
gland sparing IMRT. 
The study was done in 2006, and it had 36 patients included in whom 
parotid sparing was done. In a subset of 18 patients, where the risk of 
recurrence in the region of submandibular gland was judged to be low, 
full dose of radiation to the contralateral submandibular gland can be 
spared. 
Then, the salivary flow rates- both total unstimulated and stimulated were 
measured and monitored over a period of time and the adverse effects 
that were seen were also recorded. 
 
After a follow up period of twelve months following IMRT, the salivary 
flow rates were measured and it was found that the mean unstimulated 
saliva flow was 60% of the upfront value among patients who had 
submandibular gland spared along with parotid sparing and it was only 
25% among those who had no sparing of submandibular gland (P=0.006). 
It was also reported that patients in whom was sparing done had lesser 
grade two or higher xerostomia, 4 against 11 with a p value = 0.018.  
They were also lesser dependent on salivary substitutes. 
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After a mean follow up period of 31 months, there was no cancer 
recurrence detected in the vicinity of the spared submandibular glands. 
Hence, it was concluded that in a selected group of patients, sparing of 
submandibular gland could be safely done and it was effective in 
reducing/ preservation of radiation induced xerostomia.  
 
2. Little et al [133] 
This was a prospective study in which assessment of xerostomia was 
done in patients with head and neck cancers treated with radiation along 
with concurrent chemotherapy when along with sparing of the parotids 
using IMRT, dose to other salivary glands was also reduced. 
There were 78 patients included in this study where Stage III-IV 
oropharynx/ nasopharynx cancer underwent chemo-radiation and sparing 
the parts of the bilateral parotids, minor salivary glands in the oral cavity, 
and contralateral submandibular gland outside the target (in cases where 
the contralateral level I region was not at risk). Validated patient-reported 
xerostomia questionnaire scores and observer-graded xerostomia scores 
were recorded before the treatment and periodically over a period of 24 
months. Stimulated and unstimulated saliva flow rates were measured 
selectively from parotid and submandibular glands. The mean oral cavity 
dose acted as a replacement of minor salivary glands function.  
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On multivariate analyses, after adjusting for the PG and SMG doses, the 
OC mean dose (p < .0001), interval from RT (p < .0001), and stimulated 
PG saliva (p < .0025) were significant predictors of the XQ scores and 
the OC mean dose and time for observer-graded xerostomia. Although 
scatter plots showed no thresholds, an OC mean dose of <40 Gy and 
contralateral SMG mean dose of <50 Gy were each associated with low 
patient-reported and observer-rated xerostomia post treatment, 
This study showed that parotids, submandibular glands and oral 
cavity mean doses were significant in predicting the xerostomia rated by 
the patients and observer rated findings after completion of 
chemoradiation. These results supported that efforts to spare all the 
salivary glands beyond parotids can improve outcomes of xerostomia 
further. 
 
3. Chajon et al [134] 
This study analysed the loco-regional failure patterns in patients with 
head and neck cancer who were treated using IMRT with parotid, 
submandibular and accessory salivary glands present in the oral cavity. 
Seventy patients with Head and Neck cancers treated by definitive IMRT 
were included and analysed with a median follow up 20 months. 
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It was found that the 2 year loco regional control was 76% with one 
marginal recurrence and in field recurrences were 12 in number. But, 
there were no recurrences observed in vicinity of spared structures. It was 
also noted that the loco regional recurrence was not increased by 
lowering the mean does in the salivary glands but only dependent on the 
T and N stages.   
Taking results into consideration, it seems reasonable to execute 
treatment plans which can maintain low mean doses of radiation to the 
oral cavity accessory glands, submandibular along with the patotids.  
Sanguineti et al. [135] identified that the risk Level IB involvement even 
in patients with multiple positive neck levels with early-stage 
oropharyngeal carcinoma was found to be insignificant. 
 
4. Gensheimer et al [136] 
This had the highest number of patients (n= 114) with locally 
advanced oropharyngeal carcinoma included in the study till date  
where contralateral submandibular gland sparing was done using 
IMRT and the patterns of loco regional recurrence/ failure were 
studied. 
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Only locally advanced oropharyngeal cancers were included, to 
minimize population heterogeneity.  Around 90% of the patients were 
treated with concurrent chemoradiation. 
Of the 114 patients included in the study, 76 patients underwent 
submandibular gland sparing and 38 received unspared IMRT. Among 
the cSMG spared group, the mean SMG dose was 30.7Gy and the 
mean parotid dose on the spared side was 22.4Gy. 
Xerostomia outcomes were measured at 6, 12 and 24 months from 
completion of radiation therapy. It was found that in the unspared arm, 
Grade 2+ xerostomia was 72%, 41% and 36% respectively whereas in 
the cSMG spared arm, it was 23%, 6% and 3%. This was clinically 
significant, p<0.0007. On multivariate analysis, only cSMG dose and 
T4 tumors were found to be predictive of xerostomia. 
There was no marginal miss or recurrence in the vicinity of the sapred 
submandibular gland. 
 
 
. 
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3. AIM OF THE STUDY 
This was a study aimed at assessing the clinical advantages 
achieved with the help of contralateral submandibular gland sparing 
IMRT. It was a prospective study which focussed on the advantages of 
reducing the dose received by the major salivary glands- parotid and 
contralateral submandibular gland. The corresponding changes were 
observed in the subjective and objectively rated dryness of mouth/ throat 
at the end of treatment, at 3 months and 6 months from commencement 
of treatment. 
 The focus was on reducing the volume of the parotid gland to less 
than 30Gy and the contralateral submandibular gland to less than 39Gy 
without comprising the dose delivered to the target area. 
The primary end point of this study was to analyze the subjective 
feeling of dryness based on a patient rated questionnaire and to compare 
it with patients where sparing of the contralateral submandibular gland 
was not done. Also, the effect of xerostomia on quality of life (QoL) of 
the patients was assessed. 
The secondary end point was to measure the mean dose received by 
parotids and submandibular glands in the patients where submandibular 
sparing was done with the group of patients who were treated without 
sparing.  
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4. MATERIAL AND METHODS 
This is a prospective, longitudinal study done in patients of locally 
advanced head and neck cancer patients treated with a curative intent 
using definitive radiation therapy with/without concurrent chemotherapy 
(based on patient’s fitness).  The main objective of this study was to 
assess the xerostomia of the patients after completion of treatment. 
 
Locally advanced cancers are included in this study as they warrant 
elective irradiation of bilateral neck and to avoid population 
heterogeneity which would arise if the early cancers were to be included. 
 
In order to avoid tumour related effects on the end points of this study, 
the sites of head and neck- oral cavity and glottis larynx were not 
included in the study. 
Oral cavity cancers were not a part as level IB are the first echelon nodes 
and the sparing of submandibular region is not possible without 
significant compromise of the dose delivered to the areas at risk. Glottic 
larynx was avoided as, compared to other sites, the propensity of 
metastatic lymph node involvement is much lesser due to its poor 
lymphatic supply [116, 117, 118, 119]. 
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Study period: January to Spetember 2015 
 
Study population:  
Inclusion criteria:  
1) Oropharynx, hypopharyx and supraglottic larynx cancers  
2) Stages III and IV 
    3) Bilateral neck irradiation required 
 
Exclusion criteria: 
1)  Early stage (I, II) 
2)  Recurrent tumors 
3) Oropharynx cancer spreading onto the anterior 2/3rd of tongue 
4) ECOG PS >2 
5)  Primary tumor crossing the midline 
6)  Presence of contralateral neck nodes 
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Radiation technique: 
The principles of target selection and IMRT planning followed are as per 
the general consensus of target delineation in head and neck cancers 
(120). 
The delineation of the level II region was given importance due to its 
close proximity to the submandibular gland. 
 
These nodes can be divided into the subdigastric (jugulodigastric) nodes, 
located below the level at which the posterior belly of the digastric 
muscle crosses the jugular vein  and the more cranially located nodes 
below the base of skull . The subdigastric nodes are the main nodes 
involved when contralateral metastasis occurs, whereas the more 
posteriorly located nodes are at risk bilaterally in cases of cancer of the 
nasopharynx and in the neck side that contains other Level II-III 
metastasis [121]. 
 
A slightly smaller margin was given on the cSMG spared IMRT plans 
between the CTV and PTV so that the posterior part of the submandibular 
gland which forms the anterior border of the level II region does not 
receive higher dose.  
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While defining target volumes, the planning target volumes (PTVs) were 
created using a uniform margin of about 0.5cm from the clinical target 
volume (CTV) which accounts for the daily setup errors which were 
monitored based on daily kV portal imaging and not allowed to be 
beyond 1-1.5mm.  
 
Contouring of the two major salivary glands- the parotids and 
submandibular glands was given utmost importance and done based on 
anatomic atlases. 
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Contouring of the parotid glands 
The parotids are the largest set of salivary glands and due to their 
radiolucency are usually easily picked up distinctly on CT imaging. Its 
laterally placed position also makes it easy to demarcate the gland based   
on the structures around it. 
         
            
 
 
The cranial most part of the parotid gland(orange outline) starts at the 
level of  the mandible(black arrow with blue outline), lies infero lateral to 
the  masseter muscle   
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The caudal most part of the parotid as seen in the CT cut ends inferior to 
the submandibular gland and lies superior to the sterno cleido mastoid 
msucle. 
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Topographic view of the right parotid- anterior view 
                                                                                                                         
Lateral view- right parotid 
 
Contouring of the submandibular gland 
The submandibular glands are the next largest salivary glands and are 
placed more medially compared. They start just along the level of the 
ramus of the mandible and then extend inferiorly. 
They are a little difficult to demarcate from the adjacent muscle 
(pterygoid) as they have similar lucency. Hence, an MRI is a better 
modality of  imaging to visualise the submandibular gland, 
But, on CT imaging the submandibular gland can be identified based on 
the anatomic location relative to its adjacent structure, that is, the cranial 
of the myolohyoid muscle. 
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An 
 
 
The right submandibular gland(green otuline) as seen on this CT cut 
starts along with the cranial most portion of the mylohyoid muscle(light 
blue outline).  
The right parotid is also seen infero-lateral to the submandibular gland 
with masseter present laterally.      
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The caudal end of the submandibular gland (green outline) is easier to 
demarcate as it doesn’t have any muscles in close proximity. It ends at 
the level of the mid portion of the hyoid bone (black arrow with blue 
outline). 
Other anatomic structures around this part of the submandibular are the 
digastric muscle placed posteriorly and sterno cleido mastoid muscle 
infero-laterally. 
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           Topographic view of the right submandibular gland- anterior 
 
 
Topographic view of the right submandibular gland- lateral 
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Dose prescription 
The dose prescription includes all the targets delineated in PTV to 
receive TD- 60Gy at 200cGy/fraction for five days a week. With the help 
of in house planning systems (VARIAN), inverse IMRT plans were 
analysed and executed once target dose homogeneity is achieved. An 
optimized IMRT plan was thus generated which included the dose given 
to the delineated PTVs as per the RTOG protocol along with an 
optimization goal to try and constraint the dose to the swallowing 
structures. The salivary glands that were contoured were given dosimetric 
constraints- with the mean dose of parotid gland <30Gy and the mean 
dose of submandibular gland <39Gy. No compromise to the primary 
target PTV was allowed while sparing these structures and for achieving 
optimum dosimetric goals. 
In all patients, the prescription dose to the targets was considered 
as high priority and other critical organ dosimetric constraints were 
considered to be secondary except for maximal spinal cord dose. The 
optimized IMRT strategy for sparing of the submandibular gland was 
implemented and for purpose of the study these dose prescriptions were 
considered to be clinically significant. For the whole structures and the 
parts that over lapped the PTVs, DVH analyses were performed and 
reported.  
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Dose specifications and constraints used for the two groups 
1. cSMG unspared IMRT (control group) 
Targets 
 PTV60 for the radiological gross disease; prescribed dose 60Gy in 
30 fractions 
 
Noninvolved tissues and organs 
 Parotid gland, mean dose <26Gy or <50% receive <30Gy 
 Maximal dose to brain stem 54Gy 
 Maximal dose to spinal cord 45Gy 
 Maximal dose to mandible 70Gy 
All the non-specific tissues outside PTVs: <1% to receive <110% of 
PTV60 dose 
 
2. cSMG spared group IMRT(study group)  
The dose specifications and constraints given are the same as that for 
Standard IMRT. 
In addition, the constraint for submandibular gland mean dose of <39Gy 
was also to be followed. 
(Abbreviations: cSMG- contralateral submandibular gland, IMRT- 
intensity modulated radiation therapy, PTV60- planning target volume to 
which the dose prescribed was 60Gy ) 
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Chemotherapy 
 Patients who were deemed as fit for chemotherapy received weekly 
cisplatin (40mg/m2) for 5 weeks or 3 cycles of 3 weekly cisplatin 
(70mg/m2) along with RT. Patients in whom cisplatin was deferred, 
would be given weekly carboplatin(AUC 2). If the patient 
developed toxicity due to chemo which resulted in hindrance to 
radiation, then the chemo was discontinued. 
 
Supportive care 
 Anti-emetics and adequate hydration both before and after 
chemotherapy was delivered following standard of care. 
 Among patients having dysphagia which lead to decreased food 
intake orally, nasogastric tube intubation was initiated. 
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Evaluation of xerostomia 
All the patients who were part of the study were periodically assessed 
during the treatment and at the end of treatment, the observer rated 
grading of xerostomia was done based on the RTOG criteria. 
Then, the grading was repeated during the follow up period, 3 months 
and 6 months after commencement of radiation therapy. This usually 
coincided with first follow up and the fourth follow up visit. 
These scores were systematically noted down and recorded for all the 
patients who were part of the study and had come for regular follow up. 
  
At the end of 6 months from the commencement, that is, the fourth follow 
up or when the last recording of the observer rated grading was done, the 
patients were also given a xerostomia based QoL questionnaire in the 
language of their preference.  
This questionnaire has been developed at the University of Michigan 
(122).  
It consists of eight questions, divided into four questions related to 
dryness while eating/talking and four related to dryness at rest .The XQ 
has been found tested for reliability, validated and has been found to be 
reproducible in measuring patient-reported xerostomia(122, 123, 124 ). It 
has been independently validated by investigators at the University of 
Florida (125). 
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 The Xerostomia Questionnaire (XQ) 
 
1. Rate your difficulty in talking due to dryness  (  ) 
2. Rate your difficulty in chewing due to dryness  (  ) 
3. Rate your difficulty in swallowing solid food due to  dryness  (  ) 
4. Rate the frequency of your sleeping problems due to dryness  (  ) 
5. Rate your mouth or throat dryness when eating food (  ) 
6. Rate your mouth or throat dryness while not eating  (  ) 
7. Rate the frequency of sipping liquids to aid swallowing food  (  ) 
8. Rate the frequency of sipping liquids for oral comfort when not eating   
( ) 
 
Patients rate each item on a scale from 0 to 5 with 0 being completely 
normal/least and 5 denoting most difficult/maximum discomfort. 
Total score:  
The questions 1, 4, 6 and 8 depict the dryness that the patient experiences 
at rest, and the other questions grade the dryness the patient experiences 
while eating/ talking. 
The maximum score that can be scored is 40.  
The scoring was slightly altered for convenience of the patients but the 
questions and the importance they carried remained the same.  
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Statistical Analysis 
The dose volume effect relationships of all the xerostomia outcome 
measures and dose values were modeled using multiple regression 
analyses, with the score of xerostomia using Xerostomia Questionnaire, 
measured 6 months from commencement of radiation therapy as the 
dependent variable. Statistical significance was determined at p < 0.05. 
 
 
 
 
 
 
 
 
. 
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5. RESULTS 
Patient characteristics 
A total of 40 patients were considered for this study, 3 of them 
defaulted midway through the treatment and so the study was carried 
forward with the remaining 37 patients.  Of these patients, 17 were in the 
study arm (cSMG spared IMRT) whereas 20 were in the control arm 
(unspared arm). 
All the patients were locally advanced cancers of oropharynx (14), 
hypopharynx(16) and supraglottic larynx(7). Male to female ratio in our 
study was almost 2:1. The mean age of these patients was 59yrs.  26 
(70%) out of 37 patients received concurrent chemoradiation with weekly 
or 3 weekly CDDP (1 patient received carboplatin) and 11 (30%) patients 
received RT alone. 
Out of the 37 patients, 18 (49%) were found to be in stage III, 
17(46%) in stage IV A and 2(5%) patients belonged to stage IV B.  
 
All the characteristics of the patients and tumors are detailed in with pie 
charts.  
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16(43%)
14(38%)
7 (19%)
Site of primary
Hypopharynx
Oropharynx
SG larynx
25
12
Sex
Male
Female
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18 (49%)
17 (46%)
2 (5%)
Stage
III
IV A
IV B
11 (30%)
26 (70%)
Treatment
RT alone
CT + RT
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16 (61%)
8 (31%)
2 (8%)
Chemo
3W CDDP
W CDDP
W Carbo
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Dose volume characteristics 
Ipsilateral parotid Mean dose (in Gy) 
Spared           31 
Unspared           30 
  
Contralateral parotid 
 
Spared          24.2 
Unspared          31.9 
  
Ipsilateral SMG 
 
Spared            60 
Unspared            60 
  
Contralateral SMG 
 
Spared            33 
Unspared            60 
 
 
 
 
 72 
Field alignment in a case of Ca hypopharynx T2 N1 M0 (cSMG spared) 
 
 
Dose colour wash of the same case as mentioned above 
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Field alignment in a case of Ca SG larynx T2 N1 M0 (cSMG spared) 
 
 
Dose colour wash of the above mentioned plan 
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This was a case of Ca supraglottic larynx where the growth was in the left 
aryepiglottic fold extending onto the epiglottis and abutting the left 
pyriform fossa with left vocal cord fixity. 
Clinically, it was Carcinoma SG larynx T3 N0- Stage III 
 
 
DVH of the above mentioned patient where cSMG spared IMRT was 
used 
  
Red line- PTV                                   Violet- right SMG                    
First yellow line- spine                      Light blue- right parotid 
Dark blue- left parotid                       Second yellow line- left SMG 
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Assessment of xerostomia 
The grading for xerostomia based on the RTOG criteria was done three 
times. The first time was at the end of treatment where a score of 2 or 
higher) was seen in 76% of the patients in the cSMG sparing was done 
against 80% of the control group. There almost no difference at the end 
of treatment. 
 At the end of 3 and 6 months from commencement of treatment were 
49% and 21% respectively in the study group and, 68% and 54% in the 
control group. The difference at 6 months was statistically significant (p 
<0.009) 
 
The xerostomia questionnaire scored by the patients at the end of 6 
months showed a mean score of 13 in the study arm against a score of 24 
in the control arm. This significant difference was observed due to the 
lower dryness felt by the patients at rest in the cSMG spared arm. 
As mentioned earlier, the questionnaire had two sets of questions which 
depicted the dryness either at rest or during eating/ chewing. If the score 
was divided into two sets of questions, the set which corresponded to 
dryness during chewing/ eating did not show significant difference in 
both arms, 7 vs 10(from a total score of 20). 
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But, in the second set of questions which assessed the dryness at rest, the 
average score in the cSMG spared arm was 6 compared to 14 in the 
control arm. 
Interpretation: This, questionnaire and the result clearly indicates that the 
resting saliva was better preserved in the cSMG spared arm which 
resulted in significantly lower scores in the questions related to dryness at 
rest.  
Whereas, although the scores were low for the dryness felt during 
eating/ chewing in both the arms, there was hardly any difference 
between the two. This also is justified as in the both the groups, the 
parotid glands were spared which resulted in preservation of stimulated 
saliva which is mainly secreted by the parotid gland. 
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6. DISCUSSION 
Although there has been improvement in salivary flow rates by parotid 
sparing IMRT and it is now considered technique for treating patients 
with locally advanced head and neck cancers, like hypopharynx and 
oropharynx, it may still fall short with respect to the patient rated 
xerostomia. And this has been proved to have a significant impact on 
quality of life of patients [126, 127, 128, 129].  
In the present study, patients treated with cSMG sparing bilateral 
neck IMRT, the mean dose cSMG could be limited 33Gy. Based on both 
observer and patient rated xerostomia scores, it was found that 
xerostomia was significantly lower in the cSMG spared group compared 
to the control group, independent of parotid sparing.  
 
There are concerns that there could be increase in risk of marginal 
recurrences with aggressive cSMG sparing as adequate coverage of target 
volumes could be compromised [130, 131]. There has been a study where 
recurrences were noted in the area where parotid sparing was done [132]. 
Hence, the patient selection criteria should be very stringent and is to be 
followed with utmost care. As, reducing the side effects of treatment is 
important, it still only plays second fiddle to curing of the disease. 
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This is a CT cut of a case of Ca oropharynx where the growth is just 
crossing the midline. This increases the chance of marginal miss and 
recurrences if cSMG sparing is attempted because of close proximity of 
the lesion with the level IB region/ submandibular gland.  
 
Though the cSMG sparing could be challenging because of the areas at 
risk lying in close proximity with the organ that is being attempted to be 
spared, there have been a number of studies where this has been 
attempted with no recurrence in the region where the sparing was done. 
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The table above shows a list of major studies that have been conducted 
where cSMG sparing IMRT was used safely.  
 
The most important area on which this study was focussed on was the 
subjective assessment of xerostomia. This was carried out with a 
validated Xerostomia Questionnaire developed by the University of 
Michigan. The results obtained through the patient reported outcomes of 
the impact dryness had on the QoL indicated that sparing of contralateral 
submandibular gland resulted in significant improvement in the 
symptoms. 
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Few limitations of this study are the small sample size and the non-
randomized design which may have lead to some bias. There was also no 
recording of objective salivary flow measurements to know how it 
correlated after sparing of the submandibular gland.  
However, the observed improvement in both the observer rated xerostoia 
after 6 months and the patient reported QoL questionnaire show that 
using the technique of intensity modulation and proper planning, there 
can be significant reduction in the one of the main side effects of 
radiation therapy in Head and Neck cancers.  
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7. CONCLUSION 
This was a prospective study where the patients underwent careful 
selection based on tumor characteristics and were planned using IMRT. 
The follow up was meticulous and the result obtained showed significant 
improvement in xerostomia by limiting the dose received by the 
contralateral submandibular gland along with the parotid. 
 A multivariate analysis by taking compounding factors with a 
larger sample size can improve the strength of the study. Longer follow 
up can also shed light on the recurrence/ failure rates in both the arms. 
Although it has proven its benefit in improving the QoL of patients, the 
use of IMRT with daily imaging and time required for careful selection of 
patients and proper execution of the treatment may lead to questions 
regarding the time and the cost required for execution of this type of 
planning. So, it could be worthwhile to do a study which calculates cost/ 
benefit ratio to better understand the application of this treatment in 
Indian scenario. 
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